Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionRockefeller Capital Management L.P.
Latest Disclosed Ownership282,097 shares
Latest Disclosed Value $ 37,163,495
Rockefeller Capital Management L.P. reports 0.28% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 14, 2026 - Rockefeller Capital Management L.P. filed a 13F-HR form disclosing ownership of 282,097 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $37,163,495 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 16, 2026 disclosing 281,320 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 0.28% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 282,097 777 0.28 37,163 -6.86 0.0341
2026-03-16 2025-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 281,320 87,372 45.05 39,900 46.55 0.0718
2026-02-14 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 507,170 313,222 39,863 0.0364
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 193,948 80,719 71.29 27,226 91.31 0.0533
2025-08-14 2025-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 113,229 91,630 424.23 14,232 495.94 0.0312
2025-08-08 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 113,229 91,630 14,232 0.0179
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,599 1,729 8.70 2,389 -11.95 0.0059
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,870 549 2.84 2,712 21.83 0.0070
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,321 44 0.23 2,226 -16.09 0.0060
2024-08-12 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,277 19,277 2,654 0.0075
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -6,945 -100.00 0 -100.00
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,945 219 3.26 655 0.0025
2023-05-16 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,726 -295 -4.20 1 -100.00 0.0029
2023-03-06 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,021 -59 -0.83 838 11.58 0.0042
2022-11-02 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,080 -149 -2.06 751 6.83 0.0039
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,229 -5,313 -42.36 703 -40.17 0.0037
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,542 -199 -1.56 1,175 8.39 0.0057
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,741 -8,680 -40.52 1,084 -47.20 0.0051
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,421 -599,300 -96.55 2,053 -96.60 0.0108
2021-08-10 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 620,721 -2,176 -0.35 60,407 -0.28 0.3403
2021-05-11 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 622,897 16,005 2.64 60,574 4.13 0.4099
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 606,892 273,732 82.16 58,169 81.59 0.4406
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 333,160 259 0.08 32,034 -21.12 0.3001
2020-08-12 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 332,901 20,607 6.60 40,613 50.25 0.4250
2020-05-12 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 312,294 -10,161 -3.15 27,030 -22.02 0.3546
2020-02-07 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 322,455 -28,925 -8.23 34,661 9.47 0.4321
2019-11-12 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 351,380 -13,391 -3.67 31,662 2.81 0.4295
2019-08-09 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 364,771 139,794 62.14 30,798 55.38 0.4294
2019-05-10 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 224,977 221,302 6,021.82 19,821 7,465.27 0.2825
2019-02-12 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,675 0 0.00 262 -42.04 0.0046
2018-11-02 2018-09-30 13F Neurocrine Biosciences Common 64125C109 3,675 0 0.00 452 25.21 0.0069
2018-07-31 2018-06-30 13F Neurocrine Biosciences Common 64125C109 3,675 0 0.00 361 18.36 0.0059
2018-05-09 2018-03-31 13F Neurocrine Biosciences Common 64125C109 3,675 3,675 305 0.0050
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.